NCT07020026View on ClinicalTrials.gov

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Parkinson's Disease
Interventions
DRUG

[18F]PI-2620

All participants will undergo PET imaging using the \[18F\]PI-2620 tau-binding tracer.

Trial Locations (1)

06510

RECRUITING

Institute for Neurodegenerative Disorders / XingImaging, LLC, New Haven

All Listed Sponsors
collaborator

Institute for Neurodegenerative Disorders

OTHER

lead

Michael J. Fox Foundation for Parkinson's Research

OTHER